Core Viewpoint - The company reported a revenue of $83.55 million for the six months ending June 30, 2025, reflecting a year-on-year increase of 5.88% and a profit attributable to shareholders of $19.785 million, up 5.08% year-on-year, with a proposed special dividend of HK$0.15 (approximately $0.0192) per share [1] Group 1 - The company achieved strong year-on-year growth in the U.S. market despite tariff disruptions, indicating robust demand for its quality products [1] - Emerging markets, particularly in the Asia-Pacific and Europe, Middle East, and Africa regions, have become the main growth engines for the first half of the year due to ongoing socio-economic development [1] - The growth was partially offset by a decrease in sales in the Japanese market and a decline in average selling prices in the Chinese market [1] Group 2 - The increase in net profit was primarily driven by foreign exchange gains and reduced income tax expenses, although it was offset by decreased interest income and increased selling and marketing expenses [1]

Core Viewpoint - Yiju Medical (06929) reported a revenue of $83.55 million for the six months ending June 30, 2025, representing a year-on-year increase of 5.88% [1] - The profit attributable to shareholders for the period was $19.785 million, an increase of 5.08% year-on-year, with basic earnings per share at 2.4 cents [1] - The company proposed a special dividend of 15 Hong Kong cents (approximately 1.92 US cents) per share [1] Group Performance - Despite tariff disruptions, the company achieved strong year-on-year growth in the U.S. market, indicating robust demand for its quality products [1] - Emerging markets, particularly in the Asia-Pacific region and Europe, the Middle East, and Africa, have shown positive trends, becoming the main growth engines in the first half of the year [1] - However, the growth was partially offset by a decrease in sales in the Japanese market and a decline in average selling prices in the Chinese market [1] Financial Analysis - The net profit growth was primarily driven by an increase in foreign exchange gains and a reduction in income tax expenses [1] - This growth was partially countered by a decrease in interest income and an increase in sales and marketing expenses [1]

Core Viewpoint - The company Yiju Medical (06929) announced a special dividend of HKD 0.15 per share, to be distributed on October 6, 2025 [1] Group 1 - The special dividend reflects the company's commitment to returning value to shareholders [1] - The announcement indicates the company's financial health and ability to generate cash flow [1]

Core Viewpoint - Yiju Medical (06929) announced a special dividend of HKD 0.15 per share to be distributed on October 6, 2025 [1] Company Summary - The company is set to distribute a special dividend, indicating a positive cash flow situation and potential shareholder value enhancement [1]

發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，董事會包括執行董事錢永勛先生、劉桂禎女士及陳泳成先生；非執行董事梁鼎新先生及周伊博士；以及獨立非執行 董事陳業強先生、樓家強先生BBS、MH、JP及譚麗芬醫生。 第 2 頁 共 2 頁 v 1.1.1 第 1 頁 共 2 頁 v 1.1.1 EF001 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 業聚醫療集團控股有限公司 | | 股份代號 | 06929 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 宣派特別股息及暫停辦理股份過戶登記手續 | | 公告日期 | 2025年8月15日 | | 公告狀態 | 新公告 | | 股息信息 | | | ...

Financial Performance - Revenue for the six months ended June 30, 2025, was $83,550,000, representing a 5.9% increase compared to $78,910,000 for the same period in 2024[4] - Gross profit for the same period was $55,897,000, slightly up by 0.2% from $55,776,000 in 2024[4] - Profit attributable to owners of the company increased by 5.1% to $19,785,000 from $18,828,000 year-over-year[4] - Basic and diluted earnings per share rose to 2.40 cents, a 5.3% increase from 2.28 cents in the previous year[4] - Operating profit for the period was $16,833,000, an increase from $15,871,000 in the prior year[5] - Total comprehensive income for the period was $25,635,000, compared to $14,871,000 in 2024[6] - Revenue for the six months ended June 30, 2025, was $83,550 thousand, an increase from $78,910 thousand for the same period in 2024, representing a growth of approximately 2.0%[17] - The cost of goods sold for the six months ended June 30, 2025, was $14,857 thousand, an increase from $12,288 thousand in 2024, representing a rise of about 20.9%[22] - The income tax expense for the six months ended June 30, 2025, was $3,322 thousand, compared to $2,103 thousand in 2024, reflecting an increase of approximately 58.0%[23] - Employee benefits expenses increased to $30,959 thousand for the six months ended June 30, 2025, compared to $29,043 thousand in 2024, marking an increase of about 6.6%[22] - The depreciation of property, plant, and equipment for the six months ended June 30, 2025, was $1,212 thousand, up from $1,003 thousand in 2024, indicating a growth of approximately 20.8%[22] - The group recorded a net foreign exchange gain of $1.5 million for the six months ended June 30, 2025, compared to a net loss of $0.7 million for the same period in 2024[81] - Net income attributable to the company's owners increased by 5.1% from $18.8 million to $19.8 million, driven by increased foreign exchange gains and reduced tax expenses[75] Assets and Liabilities - Non-current assets increased to $82,543,000 from $69,553,000 as of December 31, 2024[7] - Current assets totaled $363,259,000, slightly up from $361,457,000 at the end of 2024[7] - Total liabilities decreased to $35,819,000 from $36,633,000 in the previous year[8] - Cash and bank balances decreased from $248.6 million as of December 31, 2024, to $237.1 million as of June 30, 2025, primarily due to dividend payments of $10.6 million[77] - The current ratio was approximately 12.2 times as of June 30, 2025, compared to 11.8 times as of December 31, 2024[78] - The net current asset value increased by 0.8% from $330.7 million as of December 31, 2024, to $333.5 million as of June 30, 2025[79] Revenue Breakdown - Revenue from external customers in the Asia-Pacific region was $27,311 thousand for the six months ended June 30, 2025, compared to $23,955 thousand in 2024, reflecting a growth of about 14.0%[18] - Revenue from the Asia-Pacific region increased significantly to $27.3 million, a year-on-year growth of 14.0%[44] - Revenue from Europe, the Middle East, and Africa rose by 17.0% to $22.4 million, driven by sales growth of proprietary balloon products in direct and distribution markets[45] - Revenue from Japan decreased by 14.8% to $16.1 million due to a shift in sales strategy, although marketing expenses were significantly reduced[46] - Revenue from the U.S. market increased by 20.0% to $8.0 million, attributed to significant sales growth of coronary and peripheral balloons[48] - Revenue from third-party products increased by 20.6% to $4.6 million, driven by sales growth in Indonesia[61] Corporate Governance and Compliance - The company is focused on compliance with the corporate governance code as per the listing rules, ensuring transparency and accountability[101] - The independent auditor has conducted a review of the interim financial data in accordance with the relevant standards, ensuring the integrity of the financial reporting[98] - The company is committed to adhering to the regulations set forth by the Hong Kong Stock Exchange and other applicable laws, reinforcing its operational legitimacy[101] Future Plans and Developments - The company plans to adopt new accounting standards effective January 1, 2026, which are not expected to have a significant impact on the financial position or performance[15] - The company plans to accelerate product registration in Taiwan following the acquisition of a local distributor, aiming to expand its product portfolio[57] - The company expects the new generation Scoreflex QUAD balloon to launch in Q4 2025, which is anticipated to reverse the revenue decline in the Japanese market[57] - The company is constructing its largest R&D and manufacturing facility in Hangzhou, China, expected to be operational by 2027, increasing annual production capacity by approximately 2.4 million units[55] - The group plans to utilize the net proceeds from the global offering for ongoing product development and capacity expansion, with a total expected use of $31.6 million[90] Employee and Talent Management - The group employed 1,432 employees as of June 30, 2025, with employee benefit expenses amounting to approximately $31.0 million for the six months ended June 30, 2025, compared to $29.0 million for the same period in 2024[89] - The company has adopted various incentive plans, including stock option plans and share reward plans, to motivate and retain talent[103] Dividends - The company declared a final dividend of HKD 0.10 per share (approximately USD 0.0128), totaling about USD 10.61 million for the year ending December 31, 2024[30] - The board declared a special dividend of HKD 0.15 per ordinary share, payable on October 6, 2025, in addition to a previously declared final dividend of HKD 0.10 per ordinary share[91]

Core Viewpoint - The company, Aiyu Medical (06929.HK), has scheduled a board meeting on August 15, 2025, to consider and approve its interim results for the period ending June 30, 2025, and to discuss the potential distribution of an interim dividend, among other matters [1] Group 1 - The board meeting is set for August 15, 2025 [1] - The meeting will address the approval of interim results for the six months ending June 30, 2025 [1] - The company will consider the distribution of an interim dividend, if applicable [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 香港，2025年8月4日 於本公告日期，董事會包括執行董事錢永勛先生、劉桂禎女士及陳泳成先生；非執行董事梁鼎新先 生及周伊博士；以及獨立非執行董事陳業強先生、樓家強先生 BBS、MH、JP 及譚麗芬醫生。 董事會會議召開日期 業聚醫療集團控股有限公司（「本公司」）董事會（「董事會」）茲通告謹定於二零二五年 八月十五日（星期五）舉行董事會會議，藉以（其中包括）考慮及批准本公司及其附屬 公司截至二零二五年六月三十日止之中期業績及其刊發，考慮派發中期股息（如有） 及處理其他任何事務。 承董事會命 業聚醫療集團控股有限公司 董事長、執行董事兼首席執行官 錢永勛先生 OrbusNeich Medical Group Holdings Limited 業聚醫療集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6929） ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 業聚醫療集團控股有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06929 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,200,000,000 | USD | | 0.0005 | USD | | 600,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,200,000,000 | USD | | 0.0005 | USD | | 600,000 | 本月底法定/註冊股本 ...

Core Viewpoint - The PTCA balloon industry in China is experiencing steady growth due to the increasing prevalence of cardiovascular diseases, the expansion of coronary intervention treatments, and the rise of domestic medical device manufacturers. The market size is projected to grow from 1.059 billion yuan in 2021 to 1.366 billion yuan in 2024, with expectations to exceed 2.274 billion yuan by 2030 [1][11]. Industry Overview - PTCA balloons are medical devices used in cardiovascular interventions to dilate narrowed or blocked coronary arteries, improving blood flow and myocardial supply [1]. - The industry chain consists of upstream raw materials and equipment supply, midstream production, and downstream application in various medical institutions for treating cardiovascular diseases [2]. Industry Environment - The incidence of coronary artery disease (CAD) is rising in China, with the number of patients increasing from 25.272 million in 2020 to 27.953 million in 2024, and projected to exceed 30 million by 2030 [4]. - The mortality rate for CAD has also increased significantly, indicating a growing demand for treatment options [4]. Industry Status - Percutaneous coronary intervention (PCI) is a key treatment method for CAD, with a record of 1.63 million PCI procedures performed in 2023, marking a growth rate of 26.44% [7]. - Despite the increasing number of PCI procedures, the market penetration rate in China remains low at 690.9 procedures per million people, compared to 3022.1 in the U.S., suggesting significant growth potential [9]. Competitive Landscape - The global PTCA balloon market is dominated by international giants like Boston Scientific and Medtronic, which hold over 60% market share, particularly in high-end drug-eluting balloons [13]. - Domestic companies account for 60% of the number of firms but only 40% of the market share, indicating a competitive landscape where local firms are striving to catch up through innovation [13]. Future Trends - The industry is witnessing significant technological innovation and product upgrades, with new polymer materials enhancing balloon performance and the introduction of drug-coated balloons reducing the risk of restenosis [19]. - The trend towards domestic substitution is accelerating, with local companies like MicroPort and Lepu Medical increasing their market share due to improved product quality and performance [20]. - The demand for PTCA balloons is expected to grow as their application expands beyond traditional coronary disease treatment to include peripheral and intracranial vascular diseases [21].